harrysnel schreef op 8 juni 2015 10:48:
"Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary
BOSTON & DURHAM, N.C.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Parion Sciences today announced that the companies will collaborate to develop investigational epithelial sodium channel (ENaC) inhibitors for the potential treatment of cystic fibrosis (CF) and other pulmonary diseases. Under the agreement, Vertex gains worldwide development and commercial rights to Parion's investigational ENaC inhibitors, including P-1037 and P-1055, for CF and other pulmonary diseases. P-1037 is currently being evaluated in an exploratory Phase 2a study in people with CF, regardless of genotype.
Vertex and Parion plan to begin an additional Phase 2a study that adds P-1037 to treatment with the investigational combination of lumacaftor and ivacaftor for people with CF who have two copies of the F508del mutation. Parion will receive an $80 million up-front payment from Vertex with the potential to receive additional development and regulatory milestone payments and tiered royalties related to P-1037 and P-1055 in CF and other pulmonary diseases...."
investors.vrtx.com/releasedetail.cfm?...Nb: vet zelf aangebracht.
Naast triple combi therapie met 2 correctors en 1 potentiator zoekt Vertex dus ook naar andere manieren om meer patienten te bereiken (de verschillende mutaties)/ resultaten therapie te verbeteren. Wat Morgan Stanley stelt is natuurlijk correct:
"We believe that het- 508del will likely require a triple combo (2 correctors + potentiator), and with Vertex’s 2nd gen corrector just entering clinic, GLPG may be only one year behind..."Het is alleen wel noodzakelijk om ook de andere wegen die Vertex bewandelt in het oog te houden.